Cole David K, Dunn Steven M, Sami Malkit, Boulter Jonathan M, Jakobsen Bent K, Sewell Andrew K
Department of Medical Biochemistry & Immunology, Cardiff University, School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Mol Immunol. 2008 May;45(9):2700-9. doi: 10.1016/j.molimm.2007.12.009. Epub 2008 Feb 19.
Activation of cytotoxic T cells is initiated by engagement of the T-cell receptor (TCR) with peptide-major histocompatibility class I complexes (pMHCI). The CD8 co-receptor also binds to pMHCI, but at a distinct site, and allows the potential for tripartite TCR/pMHCI/CD8 interactions, which can increase T cell antigen sensitivity. There has been a substantial interest in the effect of the pMHCI/CD8 interaction upon TCR/pMHCI engagement, and several conflicting studies have examined this event, using the soluble extracellular domains of CD8 and the TCR, by surface plasmon resonance. However, the evidence to date suggests that the TCR engages cognate pMHCI before CD8 recruitment, so the question of whether TCR engagement alters CD8 binding is likely to be more relevant to the biological order of T cell antigen encounter. Here, we have examined the binding of CD8 to several variants of the HLA A2-restricted telomerase(540-548) antigen (ILAKFLHWL) and the HLA A2-restricted NY-ESO-1(157-165) antigen (SLLMWITQC) that bind to their cognate TCRs with distinct affinities and kinetics. These interactions represent a range of agonists that exhibit different CD8 dependency for activation of their respective T cells. By using engineered affinity enhanced TCRs to these ligands, which have extended off-rates of approximately 1h compared to seconds for the wildtype TCRs, we have examined pMHCI/CD8 binding before and during TCR-engagement. Here we show that the binding of the extracellular domain of the TCR to pMHCI does not transmit structural changes to the pMHCI-CD8 binding site that would alter the subsequent pMHCI/CD8 interaction.
细胞毒性T细胞的激活是由T细胞受体(TCR)与肽 - 主要组织相容性复合体I类(pMHCI)结合启动的。CD8共受体也与pMHCI结合,但结合位点不同,并允许形成三方的TCR/pMHCI/CD8相互作用,这可以增加T细胞对抗原的敏感性。pMHCI/CD8相互作用对TCR/pMHCI结合的影响引起了广泛关注,一些相互矛盾的研究使用CD8和TCR的可溶性细胞外结构域,通过表面等离子体共振研究了这一事件。然而,迄今为止的证据表明TCR在CD8募集之前就与同源pMHCI结合,因此TCR结合是否会改变CD8结合的问题可能与T细胞遇到抗原的生物学顺序更相关。在这里,我们研究了CD8与几种HLA A2限制性端粒酶(540 - 548)抗原(ILAKFLHWL)和HLA A2限制性NY - ESO - 1(157 - 165)抗原(SLLMWITQC)变体的结合,这些抗原以不同的亲和力和动力学与其同源TCR结合。这些相互作用代表了一系列激动剂,它们在激活各自的T细胞时表现出不同的CD8依赖性。通过使用对这些配体亲和力增强的工程化TCR,与野生型TCR的秒级解离速率相比,其解离速率延长至约1小时,我们研究了TCR结合之前和期间的pMHCI/CD8结合。在这里,我们表明TCR的细胞外结构域与pMHCI的结合不会将结构变化传递到pMHCI - CD8结合位点,从而不会改变随后的pMHCI/CD8相互作用。